Delving into the Latest Updates on HeiLongJiang ZBD Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a company that specializes in the research, development, production, and sale of traditional Chinese medicine. In addition to this, the company also trades in drug and Chinese herbal medicine. The business areas of the company include both industrial and commercial sectors. The products offered by the company include Chinese medicine preparations, biological agents, and chemical agents. The company was established by Tong Hua Fang on October 28, 1996 and is based in Harbin, China.

Tags

Neoplasms

Otorhinolaryngologic Diseases

Nervous System Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
Herbal medicine	2

Top 5 Target	Count

FGFRs x VEGFR	1
Akt(Proto-oncogene proteins c-akt)	1

主要目的：以哈尔滨珍宝制药有限公司生产的布瑞哌唑片（规格：2mg）作为受试制剂，以大塚製薬株式会社持证的布瑞哌唑片（商品名：Rexulti®，规格：2mg）为参比制剂，评估空腹及餐后状态下两种制剂的生物等效性。次要目的：评价受试制剂布瑞哌唑片（规格：2mg）和参比制剂布瑞哌唑片（商品名：Rexulti®，规格：2mg）在健康受试者中的安全性。

[Translation]

main purpose: The test preparation was bripipiprazole tablets (specification: 2 mg) produced by Harbin Zhenbao Pharmaceutical Co., Ltd., and bripipiprazole tablets (trade name: Rexulti®, specification: 2 mg) certified by Otsuka Manufacturing Co., Ltd. Reference preparation to evaluate the bioequivalence of two preparations in fasting and postprandial states. Secondary purpose: To evaluate the safety of the test preparation Bripipiprazole Tablets (specification: 2 mg) and the reference preparation Bripipiprazole Tablets (trade name: Rexulti®, specification: 2 mg) in healthy subjects.

Start Date26 Dec 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

CTR20233628 / CompletedNot Applicable

盐酸莫西沙星片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose (fasting/postprandial) oral bioequivalence study of moxifloxacin hydrochloride tablets in healthy Chinese subjects: two-formulation, two-sequence, two-period, crossover

主要目的：观察中国健康受试者在空腹/餐后状态下单次口服受试制剂盐酸莫西沙星片（规格：0.4g；生产企业：哈尔滨珍宝制药有限公司）和参比制剂盐酸莫西沙星片（商品名：Avelox®（拜复乐）；规格：0.4g；生产企业：Bayer HealthCare Manufacturing.S.r.l.；持证商：Bayer Vital GmbH）后的药代动力学特征，评价空腹/餐后状态下两种制剂的生物等效性。次要目的：观察受试制剂盐酸莫西沙星片和参比制剂盐酸莫西沙星片（Avelox®）在中国健康受试者中的安全性。

[Translation]

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Moxifloxacin Hydrochloride Tablets (Specification: 0.4g; Manufacturer: Harbin Zhenbao Pharmaceutical Co., Ltd.) and the reference preparation Moxifloxacin Hydrochloride Tablets (Trade name: Avelox®; Specification: 0.4g; Manufacturer: Bayer HealthCare Manufacturing. S.r.l.; Licensee: Bayer Vital GmbH) after a single oral administration in the fasting/postprandial state in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation Moxifloxacin Hydrochloride Tablets and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®) in healthy Chinese subjects.

Start Date12 Dec 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

CTR20230411 / CompletedNot Applicable

一项单中心、随机、开放、单剂量、两周期、两序列、交叉试验评价两种富马酸比索洛尔片（规格：5 mg）空腹和餐后状态下在中国健康人群中的生物等效性

[Translation] A single-center, randomized, open-label, single-dose, two-period, two-sequence, crossover study to evaluate the bioequivalence of two bisoprolol fumarate tablets (strength: 5 mg) in the fasting and fed state in healthy Chinese subjects

以哈尔滨珍宝制药有限公司生产的富马酸比索洛尔片（规格：5 mg）作为受试制剂，以Merck Serono GmbH持证的富马酸比索洛尔片（商品名：康忻®；规格：5 mg）为参比制剂，评估受试制剂和参比制剂在空腹及餐后条件下给药时的生物等效性，评价受试制剂富马酸比索洛尔片（规格：5 mg）和参比制剂富马酸比索洛尔片（商品名：康忻®，规格：5 mg）在健康受试者中的安全性。

[Translation]

Bisoprolol fumarate tablets (specification: 5 mg) produced by Harbin Zhenbao Pharmaceutical Co., Ltd. was used as the test preparation, and bisoprolol fumarate tablets (trade name: Kangxin®; specification: 5 mg) certified by Merck Serono GmbH was used as the reference preparation. The bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions was evaluated, and the safety of the test preparation bisoprolol fumarate tablets (specification: 5 mg) and the reference preparation bisoprolol fumarate tablets (trade name: Kangxin®, specification: 5 mg) in healthy subjects was evaluated.

Start Date23 Mar 2023

Sponsor / Collaborator

Haerbin Zhenbao Pharmacy Co. Ltd.

100 Clinical Results associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Login to view more data

6

Literatures (Medical) associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

06 Aug 2021·Organic LettersQ1 · CHEMISTRY

Rhodium-Catalyzed Regioselective Formal Hydroacylation of Vinyl Epoxides toward Esters Involving β-Carbon Cleavage

Q1 · CHEMISTRY

Article

Author: Li, Hong-Shuang ; Wang, Xiaodan ; Han, Junfen ; Chang, Zhi-Xin ; Zhang, Tongbo ; Gong, Fei-Yuan

Herein we disclose the first example of the formal hydroacylation reactions of vinyl epoxides with chelating aldehydes enabled by rhodium catalysis for the efficient construction of functionalized esters. Detailed investigations of the mechanistic pathway reveal that the presence of a 2-vinyl group is essential in contributing to the success of this regioselective reaction, which might proceed through β-carbon cleavage as the key procedure.

02 Jan 2021·Pharmaceutical Development and TechnologyQ4 · MEDICINE

Novel biomimetic nanostructured lipid carriers for cancer therapy: preparation, characterization, and in vitro/in vivo evaluation

Q4 · MEDICINE

Article

Author: Guo, Biru ; Cao, Lixin ; Zhou, Jianwen ; Sui, Xiaoyu ; Ma, Xiaoxing ; Han, Cuiyan ; Qian, Jiayi ; Zhu, Wenquan

Nanostructured lipid carriers (NLC) have become a research hotspot, wherein cancer-targeting effects are enhanced and side effects of chemotherapy are overcome. Usually, accelerated blood clearance (ABC) occurs after repeated injections, without changing the immunologic profile, despite PEGylation which prolongs the circulation function. To overcome these problems, we designed a red blood cell-membrane-coated NLC (RBCm-NLC), which was round-like, with a particle size of 60.33 ± 3.04 nm and a core-shell structure. Its stability was good, the drug paclitaxel (PTX) release from RBCm-PTX-NLC was less than 30% at pH7.4 and pH6.5, and the integrity of RBC membrane surface protein was maintained before and after preparation. Additionally, in vitro assays showed that, with the RBCm coating, the cellular uptake of the NLC by cancer cells was significantly enhanced. RBCm-NLC can avoid recognition by macrophage cells and prolong circulation time in vivo. In S180 tumor-bearing mice, the DiR-labeled RBCm-NLC group showed a stronger fluorescence signal and longer retention in tumor tissues, indicating a prompt tumor-targeting effect and extended blood circulation. Importantly, RBCm-PTX-NLC enhanced the antitumor effect and extended the survival period significantly in vivo. In summary, biomimetic NLC offered a novel strategy for drug delivery in cancer therapy.

01 Jan 2017·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Anti-platelet adhesive effect and mechanisms of Xueshuantong capsules under flow conditions].

Article

Author: You, Yun ; Chen, Ying ; Zhang, Qian ; Ge, Yi-Meng ; Han, Shu-Xian ; Han, Bing ; Liao, Fu-Long ; Xiang, Yan-Hua

To investigate the anti-platelet adhesive effect and possible mechanisms of Xueshuantong capsule (XST) under flow conditions. Human umbilical vein endothelial cells (HUVECs) and human platelets were employed as experimental materials, and TNF-α (20 μg•L⁻¹) was used to establish vascular endothelial cell injury models. In vivo flow conditions were simulated under controlled shear stress of 0.1 Pa and 0.9 Pa by Bioflux1000 assays accordingly. Anti-platelet adhesive effects of XST at 0.3 g•L⁻¹ were dynamically monitored by microscopic time-lapse photography. Western blotting was employed to detect the VCAM-1 expression on endothelial cells, and the release of 6-keto-PGF1α and TXB2 was tested by radioimmunoassay. The results showed that XST could inhibit the platelets adhesion under both physiological and pathological flow conditions, and the inhibition rate was 15.0% and 34.1% respectively. Under pathological low shear stress or static conditions, XST could significantly inhibit endothelial cells VCAM-1 expression and TXB2 release (P<0.05). These results suggested that XST inhibited platelets adhering to injured endothelium via decreasing VCAM-1 expression and TXA2 secretion from endothelium. From the interactions among blood flow, vascular endothelium and platelets, the anti-thrombosis effects of XST were possibly related to endothelial cells protection and therefore inhibiting platelets adhesion. Under different flow conditions, the antiplatelet adhesion effect of XST was different, and the pathological low shear stress was more conducive to the efficacy of XST.

100 Deals associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with HeiLongJiang ZBD Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

2

Phase 1 Clinical

Approved

2

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XueShuanTong Capsule	Brain Infarction More	Approved
FuFangQinlan	Common Cold More	Approved
HZB0071 ( Akt )	Neoplasms More	Phase 1
HZB1006 ( FGFRs x VEGFR )	Liver Cancer More	Phase 1
Qingjianghewei Granules	Non-erosive gastro-esophageal reflux disease More	IND Approval